

Inventors: Steward et al.  
Serial No.: 09/942,098  
Filed: August 28, 2001  
Page 2

- Group 1 : Claims 1-3, 4-8 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype A;
- Group 2 : Claims 1, 2, 9-13 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype B;
- Group 3 : Claims 1-3, 14-20 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype C1;
- Group 4 : Claims 1-3, 21-25, and 45-66 (in part), drawn to a substrate for botulinum toxin serotype D;
- Group 5 : Claims 1-3, 26-30 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype E;
- Group 6 : Claims 1-3, 31-35 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype F;
- Group 7 : Claims 1-3, 36-39 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype G;
- Group 8 : Claims 1-3, 40-44 and 45-66 (in part), drawn to a substrate for tetanus toxin;

Inventors: Steward et al.  
Serial No.: 09/942,098  
Filed: August 28, 2001  
Page 3

- Group 9 : Claims 68-70 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype A;
- Group 10 : Claims 68-69, 71 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype B;
- Group 11 : Claims 68-69, 72 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype C1;
- Group 12 : Claims 68-69, 73 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype D;
- Group 13 : Claims 68-69, 74 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype E;
- Group 14 : Claims 68-69, 75 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype G;
- Group 15 : Claims 68-69, 76 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype G; and

Inventors: Steward et al.  
Serial No.: 09/942,098  
Filed: August 28, 2001  
Page 4

Group 16 : Claims 68-69, 77 and 78-95 (in part),  
drawn to a method using a substrates for  
tetanus toxin.

Applicant assumes that claim 67, which was not  
mentioned in the Restriction Requirement, is to be grouped with  
claims 45 to 66. If this assumption is not correct, the Examiner  
is requested to contact the undersigned agent.

Applicant hereby elects without traverse the claims of  
Group I (claims 1 to 3, 4 to 8 and 45 to 67 (in part)), drawn to  
a BoNT/A clostridial toxin substrate.

### III. CONCLUSION

In view of the remarks submitted herein, Applicants  
respectfully request that the claims of Group I be examined.

The Examiner is invited to call the undersigned agent  
or Cathryn Campbell if there are any questions regarding this  
application.

Respectfully submitted,

July 9, 2003  
Date

4370 La Jolla Village Drive  
Suite 700  
San Diego, California 92122

Andrea L. Gashler  
Andrea L. Gashler  
Registration No.: 41,029  
Telephone: (619) 535-9001  
Facsimile: (619) 535-8949